1

NAME (Last, First, Title):

Bar Jair, M.D. Ph.D.

POSITION TITLE

Deputy Director, Institute of Oncology

Sheba Medical Center

ACADEMIC DEGREE: Senior Lecturer

Academic track, Tel Aviv University, since Oct 2015

Address (office): Institute of Oncology

The Chaim Sheba Medical Center

Tel Hashomer, 5262000, Israel.

E-mail: yair.bar@sheba.health.gov.il

EDUCATION

INSTITUTION,

LOCATION DEGREE YEAR(s) FIELD OF STUDY

The Hebrew University-

Hadassah School

Jerusalem, Israel

B.Sc. 1990-1993 Medicine

M.D. 1993-1997 Medicine

Weizmann Institute of

Science, Rehovot, Israel Ph.D. 2000-2004 Molecular Biology

Sheba Medical Center, Tel-

Hashomer, Israel.

Specialist in

Oncology 2004-2009

Medical and Radiation

Oncology

The Ottawa Hospital Cancer

Center, Ottawa, Canada.

Fellowship of

Thoracic

Medical

Oncology

2009-2011 Thoracic Medical

Oncology

Additional Certificates: Medical Specialist license, Oncology (Medical & Radiotherapy), Israel. 2009

License to practice medicine, Israel, Unrestricted (#30252) 1998

Work / training positions:

2014- Deputy Director, Institute of Oncology, Sheba Medical Center, Israel.

2013- Chairman of the Israel Lung Cancer Group.

2011- Head, Thoracic Oncology, Medical & Radiation Oncology, Institute of

Oncology, Sheba Medical Center, Israel.

2011- Head, Novel Therapeutics for Lung Cancer Lab, Institute of Oncology, Sheba

Medical Center, Israel.

2009-2011 Clinical & Research Fellow, Medical Oncology, The Ottawa Hospital, Ottawa,

ON, Canada.

2004-2009 Resident, Oncology (Medical and Radiotherapy), Sheba Medical Center,

Israel.

2005-2008 Investigator, an independent research lab at the Sheba Cancer Research Center,

Israel.

1998-2004 Physician (part-time), Internal Medicine, Sheba Medical Center, Israel.

1998-2000 Research fellow, the Weizmann Institute of Science, Israel.

2

Other activities:

Editorial board member of Annals of Thoracic Oncology Research since 2017.

Editorial board member of MEMO (Magazine of European Medical Oncology) since 2013.

PI on most industry-sponsored lung cancer trials in the Sheba Oncology Institute, since 2012.

PI and initiator of many clinical investigator initiated trials (latest; NCT01932229,

NCT02938624).

Co-Investigator on clinical trials of the National Cancer Institute Canada – Clinical Trials

Group (NCIC-CTG) 2009-2011.

Grant reviewer for Israel Science Foundation, ‘Israel Cancer Fund’, the Israeli Health

Ministry Chief Scientist, 'The Netherlands Organization for Health Research and

Development', ‘Bi-national Science Foundation’.

A reviewer for Lung cancer, Clinical Lung Cancer, PLOS ONE, Cancer Science, Cancer

Microenvironment, J of Chemotherapy, Pharmaceutical Research, International Journal for

Biotechnology, Molecular Biology Research and Expert Opinion on Drug Delivery journals.

Peer-reviewed Publications:

*Dudnik E, *Bar J, Peled N, Bshara E, Kuznetsov T, Cohen AY, Shochat T, Nechushtan H,

Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadar N, Urban D, Mishaeli M,

Maimon Rabinovich N, Brenner R, Zer A, Rotem O, Roisman LC, Wollner M. Efficacy and

safety of BRAF inhibitors (BRAFi) +/- MEK inhibitors (MEKi) in BRAF mutant (BRAFm)

advanced non-small cell lung cancer (NSCLC): findings from the real-life cohort. Accepted

to Clinical Lung Cancer, March 2019 *Equal contribution

Appel S, Bar J, Ben-Nun A, Perelman M, Alezra D, Urban D, Ben-Ayun M, Honig N, Ofek

E, Katzman T, Onn A, Chatterji S, Dubinski S, Tsvang L, Felder S, Kraitman J, Haisraely O,

Rabin Alezra T, Lieberman S, Marom EM, Golan NG, Simansky D, Symon Z, Lawrence YR.

Comparative effectiveness of intensity modulated / volumetric arc to 3-dimensional

conformal radiation in locally advanced lung cancer: pathological and clinical and outcomes.

Accepted to Br J Radiol 2019; 92: 20180960.

Bedas A, Peled N, Rabinovich NM, Mishaeli M, Shochat T, Zer A, Rotem O, Allen AM, Bar

J, Dudnik E. Efficacy and safety of ALK tyrosine kinase inhibitors (ALK TKIs) in the elderly

patients with advanced. ALK-positive non-small cell lung cancer (NSCLC): findings from the

real-life cohort. February 2019 Accepted to Oncology Research and Treatment.

Eshet Y, Baruch E, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G,

Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J, Boursi B, and Markel G. Clinical

significance of pancreatic atrophy induced by immune checkpoint inhibitors: A case-control

study. Cancer Immunology Research, December 2018, 6(12). DOI: 10.1158/2326-6066.CIR-

17-0659.

A. Ben Nun, N. Golan, E. Ofek, D. Urban, I. Kamer, D. Simansky, A. Onn, A. Ackerstein,

S.P. Raskin, T. Shulimzon, N. Zeitlin, I. Redinsky, S. Halperin, M. Jurkowicz and J. Bar.

Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC) –

initial report of a phase I study, MK3475-223. Annals of Oncology, 29(suppl_8), October

2018, mdy290.011.

J. Bar, K. Shulman, T. Kuznetsov, G. Markel, S. Daher, R. Berger, T. Golan, D. Urban, T.

Sela, E. Shacham Shmueli, R. Klempfner, A. Talianski, A. Onn, E. Dudnik Evaluation of a

possible link between immunotherapy (IO) and acute vascular events. Annals of Oncology,

29(suppl_8), October 2018, mdy288.090.

3

Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, Moskovitz M, Keren S,

Popovits-Hadari N, Urban D, Mishaeli M, Zer A, Allen AM, Maimon Rabinovich N, Rotem

O, Kuznetsov T, Shochat T, Roisman LC, Bar J, on behalf of the Israel Lung Cancer Group.

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational

Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.

Journal of Thoracic Oncology, August 2018, 13(8):1128-1137

Bar J, Urban, D Kuznetsov T, Gadot M, Zadok O, Kamer I, Perelman M, Onn A, Ofek E.

Small cell transformation as a mechanism of resistance to immunotherapy of non-small cell

lung cancer. J Clin Oncol, 36(15) suppl, June 2018, DOI:

10.1200/JCO.2018.36.15_suppl.e21230 36

Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman M, Srivastava S,

Ghosh S, Lindzen M, Salame TM, Onn A, Bar J, and Yarden Y. A Combination Of

Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking

Bypass Pathways. Clinical Cancer Research, June 2018, DOI: 10.1158/1078-0432.CCR-18-

0450

Dudnik E, Moskovitzb M, Daher S, Shamai A, Hanovich E, Grubstein A, Shochat T, Wollner

M, Bar J, Merimsky O, Zer A, Daniel Z, Goldstein A, Hammerman A, Cyjon A, Shechtman,

Y Abu-Amna M, Flex D, Roisman LC, Peled N. On behalf of the Israel Lung Cancer Group.

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life

data. Lung Cancer, November 2017, https://doi.org/10.1016/j.lungcan.2017.11.015.

Dudnik E, Peled N, Wollner M, Onn A, Agbareya, A Nechushtan H, Kuznetsov T, Roisman

L, Belilovski Rozenblum A., Geva S, Zer A, Bar J. BRAF Mutant NSCLC: Correlation with

PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy. MA 02.06,

Journal of Thoracic Oncology. November 2017, 12(11), Sup. 2, S1804–S1805. DOI:

https://doi.org/10.1016/j.jtho.2017.09.455

Allen AM, Urban D, Dudnik J, WollnerM, Agbarya A, Rosenberg SK, Moskovitz M and Bar

J. Real-World Practice Patterns in the Treatment of Stage III Non-Small Cell Lung Cancer;

the Israeli Experience. Annals of Thoracic Oncology Research, 2017 August; 1(2): 1006.

Shlomi D, Abud M, Liran O, Bar J, Gai-Mor N, Ilouze M, Onn M, Ben-Nun A, Haick H,

Peled N. Detection of Lung Cancer and EGFR Mutation by Electronic Nose System. Journal

of Thoracic Oncology, 2017 July, 12(10);1544-1551.

https://doi.org/10.1016/j.jtho.2017.06.073

Dudnik E, Roisman LC, Bar J, Hammerman A, Daher S, Moskovitz M, Shamai S, Hanovich

E, Shechtman Y, Abu-Amna M, Zer A, Wollner M, Merimsky O, Cyjon A, Peled N On

behalf of the Israeli Lung Cancer Group Economic aspects of nivolumab in non-small cell

lung cancer (NSCLC): lessons from real-life. Journal of Clinical Oncology 35, no. 15_suppl

e18322

Dagan A, Sella T, Urban D, Onn A, Bar J*, Segal G*. Low ALT is not associated with

Increased Rate of Mortality in Patients with Advanced Lung Cancer. *equal contribution.

Journal of Cachexia, Sarcopenia and Muscle ‐ Clinical Reports, 2017, 2(1), e00016, P. 1.

Appel S, Goldstein J, Perelman M, Rabin T, Urban D, Onn A, Shulimzon TR, Weiss I,

Lieberman S, Marom EM, Golan N, Simanski D, Ben-Nun A, Lawrence YR, Bar J *, Symon

Z * Definitive dose Chemo-radiation followed by Surgery for Locally Advanced Non-Small

Cell Lung Cancer Patients; Evaluation of Trimodality Strategy *equal contribution.

Accepted to IMAJ Feb 2017.

Shiran I, Heller E, Jessel S, Kamer I, Meshulam I, Navon R, Urban D, #Onn A, #Bar J.

NSCLC Patients with adenocarcinoma morphology have better prognosis than patients

4

diagnosed with NSCLC favor adenocarcinoma. # equal contribution. Clinical Lung Cancer,

18(3): 316–323.e1. May 2017. http://dx.doi.org/10.1016/j.cllc.2017.01.009.

Appel S, Lawrence YR, Goldstein J, Pfeffer RM, Weiss I, Rabin T, Felder S, Ben-Ayun M,

Tzvang L, Alezra D, Simansky D, Ben-Nun A, Bar J, Symon Z. Stereotactic Ablative Body

Radiation for Stage I Lung Cancer in Israel: A Retrospective Single-Center Report. IMAJ

2017 January; 19: 39-43.

Bar J, Gorn I, Hasim MS, Baghai T, Hanson JEL, Niknejad N, Perkins TJ, Stewart DJ, Sekhon

HS, Villeneuve PJ and Dimitroulakos J. Induction of Activating Transcription Factor 3 is

associated with cisplatin responsiveness in NSCLC: A potential predictive biomarker of

response. Neoplasia. 2016 September; 18(9): 525–535.

Appel S, Goldstein JD, Symon Z, Lawrence Y, Bar J, Rabin T, Ben Ayun M, Davidson T,

Ben Nun A. Does Pathologic Response to Neoadjuvant Chemoradiation to 60 Gy Predict

Survival in Locally Advanced Non-Small Cell Lung Cancer? Int J Rad Onc Biol Phys 2016

Oct; 96(2): Sup E465.

Appel S, Lawrence YR, Bar J, Ben Nun A. Concomitant chemo-radiation to 60 Gy followed

by surgery for locally advanced non-small cell lung cancer patients; evaluation of trimodality

strategy. J Thor Onc. 2016 April; 11(4): Sup S109. Abstract 122P ELCC 2016.

Leibowitz-Amit R, Shapira-Frommer R, Golan T, Korach L, Israel A, Shalem Y, Shacham-

Shmueli E, Ben-Ami E, Hausner D, Zach L, Nili Gal-Yam E, Kaufman B, Onn A, Urban D,

Bar J, Berger R. Initial clinical experience with pembrolizumab in metastatic heavily pre-

treated patients with solid cancers in a single institution. Eur J Cancer, September 2015

51(sup 3); S111.

Feinberg T, Alkob L, Herbig J, Cancilla J, Torrecilla J, GaiMor N, Bar J, Ilouze M, Haick H,

Peled N. Cancerous glucose metabolism in lung cancer – evidence from exhaled breath

analysis. Journal of Breath Research, 2016 June; 10(2): doi:10.1088/1752-7155/10/2/026012.

Nisman B, Nechushtan H, Biran H, Peled N, Gantz-Sorotsky H, Doviner V, Perelman M, Bar

J, Onn A, Uziely B, Peretz T. New ARCHITECT plasma pro-gastrin-releasing peptide assay

for diagnosing and monitoring small-cell lung cancer. British Journal of Cancer 2016; 114:

469–476. doi:10.1038/bjc.2016.7.

Ben Nun A, Simansky D, Rokah M, Zaytlin N, Ben Avi R, Soudack M, Golan N, Apel S,

Bar J, Yelin A. Hybrid video-assisted and limited open (VALO) resection of superior sulcus

tumors. Surgery Today. 2016; 46: 686. doi:10.1007/s00595-015-1225-0.

Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD,

Dimitroulakos J, and Bradbury PA. Angiotensin Converting Enzyme and Aldosterone Serum

Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group

study BR.24. Clin Lung Cancer. 2015 Nov;16(6):e189-201. doi: 10.1016/j.cllc.2015.05.002.

Epub 2015 May 13. PubMed PMID: 26081815.

Bar J, Botser D, Navon R, Peled N, Biran H, Nili Gal-Yam E, Ben-Arieh S, Raskin S, Onn

A; A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small

cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI)

resistance. J Clin Oncol 33, 2015 (suppl; abstr e19031).

Bar J, Gottfried M, Dudnik J, Flex D, Keren-Rosenberg SP, Agbarya A, Onn A, Moskovitz

MT, Maimon N, Lazarev I, Peled N, Popovits-Hadari N, Biran H, Urban D, Herscovici L,

Wollner M. Prognostic impact of first treatment choice in EGFR mutant non-small cell lung

cancer (mNSCLC) patients (pts) per mutation type; retrospective analysis. J Clin Oncol 33,

2015 (suppl; abstr e19120).

5

Nisman B, Nechushtan H, Biran H, Peled N, Gantz-Sorotsky H, Doviner V, Perelman M, Bar

J, Uziely B, Peretz-Yablonski T. New ARCHITECT plasma pro-gastrin-releasing peptide

assay and lung cancer: Implications for diagnosis, follow-up, and prognosis. J Clin Oncol 33,

2015 (suppl; abstr 7570).

Katanov C, Lerrer S, Liubomirski Y, Lieder-Trejo L, Meshel T, Bar J, Feniger-Barish R,

Kamer I, Soria-Artzi G, Kahani H, Banerjee D and Ben-Baruch A. Regulation of the

inflammatory profile of stromal cells in human breast cancer: Prominent roles for TNF-alpha

and the NF-kappaB pathway. Stem Cell Research & Therapy 2015 May; 6:87

doi:10.1186/s13287-015-0080-7.

Bar J, Gorn-Hondermann I, Moretto P, Perkins TJ, Niknejad N, Stewart D, Goss G,

Dimitroulakos J. Cyclin dependent kinase 6 down-regulation as a potential mechanism of

acquired cisplatin resistance in non-small cell lung carcinoma. Clin Lung Cancer. 2015

Nov;16(6):e121-9. doi: 10.1016/j.cllc.2015.01.008. Epub 2015 Feb 3. PubMed PMID:

25703099.

Sella T, Botser D, Navon N, Biran H, Tenenbaum S, Urban D, Onn A, Bar J. Preferences for

disclosure of disease related information among thoracic cancer patients. Lung Cancer 2015

Apr;88(1):100-3. doi: 10.1016/j.lungcan.2015.01.021. Epub 2015 Jan 31.

Shlomi D, Ben-Nun A, Kaplan T, Ilouze M, Simanski D, Shulimzon T, Gai-Mor N, Cohen L,

Golan N, Baltaxe E, Bar J, Onn A, Onn A, Peled N. Automated target-FISH lung cancer

detection (LCD) test of induced sputum. European Respiratory Journal 2015 46: PA3002;

DOI: 10.1183/13993003.congress-2015.PA3002

Agbarya A, Melamed-Frank M, Kaidar-Person O, Goldberg-Cohen I, Nasrallah H, Wollner

M, Bar J, Rennert G, Lejbkowicz F. Getting out of a wheelchair: an uncommon insertion

mutation in exon 19 of EGFR responsive to erlotinib. SpringerPlus. 2014; 3:507

DOI: 10.1186/2193-1801-3-507.

Bar J, Cyjon A, Dov F, Sorotsky H, Biran H, Dudnik J, Peylan-Ramu N, Peled N,

Nechushtan H, Gips M, Katsnelson R, Keren SR, Merimsky O, Onn A, Gottfried M, on

behalf of the Israeli Lung Cancer Group. EGFR mutation testing in advanced non-small cell

lung cancer. Lung May 2014; 192(5): 759-763. DOI 10.1007/s00408-014-9604-7.

Bar J, Damianovich M, Hout Siloni G, Dar E, Cohen Y, Zadok O, Cohen Y, Perelman M,

Barshack I, Yarden RI, Simansky D, Ben Nun A, Onn A. Evaluation of EGFR, KRAS and

TP53 mutations as predictive of disease recurrence in resected early non-small cell lung

carcinomas (NSCLC). MEMO, 2014 February; 7(1): 10-15.

Bar J, Damianovich M, Hout Siloni G, Dar E, Cohen Y, Perelman M, Ben Nun A, Simansky

D, Yellin A, Urban D, Onn A. Genetic mutations screen in early non small cell lung cancer

(NSCLC) specimens. Clinical Lung Cancer, 2014 March, 15(2): 159–165.

Bar J, Spencer S, Morgan S, Pike L, Cunningham D, Robertson J, Jürgensmeier JM, Goss

GD. Correlation of LDH isoenzyme profile with outcome in advanced colorectal cancer

patients treated with chemotherapy and bevacizumab or cediranib (HORIZON I study).

Clinical Colorectal Cancer, March 2014; 13(1): 46–53.

Shlomi D, Onn A, Gottfried M, Bar J, Biran H, Ilouze M, Dvir A, Nechushtan H, Soussan-

Gutman L, Peled N. Better Selection Model for EML4-ALK Fusion Gene Test in Patients

with Non-Small-Cell Lung Cancer. Journal of Cancer Therapy, 2013, 4, 54-58

Bar J, Ding K, Zhao H, Laurie SA, Shepherd F, Addison C, Goss GD, Dimitroulakos J,

Bradbury PA. Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone

(Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial. J

Clin Oncol 31, 2013 (suppl; abstr 8048). [IF 2011: 18.372]

6

Urban D, Bar J, Solomon B, Ball D. Lymph node ratio may predict the benefit of

postoperative radiotherapy in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology,

2013 Jul;8(7):940-6.

Bar J, Spencer S, Morgan S, Pike L, Cunningham D, Robertson J, Jürgensmeier JM, Goss

GD. Correlation of lactate dehydrogenase (LDH) isoenzyme profile with outcome in

advanced colorectal cancer (CRC) patients (pts) treated with chemotherapy and bevacizumab

(BEV) or cediranib (CED). J Clin Oncol. 30, 2012 (suppl; abstr e13541). [IF 2011: 18.372]

Biran H, Perelman M, Bar J, Zwas TS. Somatostain receptor (SSTR)-targeted therapy in

pulmonary large-cell neuroendocrine carcinoma (LCNEC) patients with intermediate

proliferation rate (PR). J Clin Oncol 30, 2012 (suppl; abstr e17509). ). [IF 2011: 18.372].

Shiran I, Borshteen R, Urban D, Onn A, Biran H, Bar J. The efficacy of pemetrexed-

based treatment for advanced non-small cell lung cancer (NSCLC), as correlated with the

pathologic features of tumors. Journal of Thoracic Oncology. 2012 June; 7 Sup 1, S45.

Bar J, Ng D, Moretto P, Goss DG, Sun A, MacRae R, Laurie S, Leighl N and Nicholas G.

Chemoradiotherapy for recurrent NSCLC; retrospective database analysis of two large cancer

centers. Clinical Lung Cancer. 2013 March; 14(2). 200-4.

Vickers MM*, Bar J*, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JEL,

Addison CL, Asmis TR, Jonker DJ, Maroun J, Lorimer IAJ, Goss DG and Dimitroulakos J.

Stage-dependant differential expression of microRNAs in colorectal cancer: Potential role as

markers of metastatic disease. Clinical and Experimental Metastasis. 2012 Feb; 29(2). 123-

132. *Equal contribution. [IF 2010: 4.113]

Gomes M, Souza C, Bar J, Sekhon H. Interdisciplinary site-specific didactic meetings:

Interdisciplinary site-specific didactic meetings: Addressing competency-based education and

program-based clinical services. International Conference on Residency Education 2011,

Royal College of Physicians and Surgeons of Canada. Open Medicine. September 21, 2011.

Vol. 5(3), pp.S10, abstract 159.

Bar J, Gorn-hundermann I, Reid S, O’Brien A, Niknejad N, Goss GD, Dimitroulakos J.

Activating transcription factor 3 (ATF3) as a potential biomarker of platinum sensitivity in

non-small cell lung cancer (NSCLC). J Clin Oncol. 29: 2011 (suppl; abstr e21012). [IF 2011:

18.372]

Bar J, Perez-Iratxeta C, Gorn-hundermann I, Reid S, Goss G, Dimitroulakos J. microRNA

(miR) analysis as a tool for discovering platinum resistance mechanisms in non-small cell

lung cancer (NSCLC). 2011 Proceedings of the American Association for Cancer Research.

Abstract #4949.

Vickers MM, Asmis T, Jonker D, Maroun JA, Yarom N, Bar J, Gorn-Hundermann I,

Daneshmand M, Dimitroulakos J. Metastasis suppressing/promoting microRNA expression in

primary and metastatic colorectal cancer. Ann Oncol. 2010 Oct; 21, sup (8): viii49 (102P).

Gorn I, Bar J, Vickers MM, Dimitroulakos J. Optimization of microRNA (miRNA)

extraction from formalin fixed paraffin embedded (FFPE) colorectal and lung cancer tissues,

and validation of a microRNA internal control. Ann Oncol. 2010 Oct; 21, sup (8): viii60

(147).

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C and Barshack I. Breast cancer

Her2 equivocal cases: is there an alternative to FisH testing? a Pilot study Using two

Different antibodies sequentially. IMAJ, 2010 June; 12: 78-81.

7

Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser M, Bar J, Shapira

R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A and Schachter J.

Systemic dysregulation of CEACAM1 in the melanoma patients. Cancer Immunology

Immunotherapy, 2010 February; 59(2): 215-230. [IF 3.728 2007].

Bar J., Feniger-Barish R., Moskovits N, Lukashchuk N, Goldfinger N, Rotter V, Goss G,

Oren M. Cancer cells suppress p53 in adjacent fibroblasts. Journal of Thoracic Oncology

2009 September; 4(9) Sup (1): S605.

Bar J , Feniger-Barish R., Lukashchuk N, Shaham H, Moskovits N, Goldfinger N, Simansky

D, Perlman M, Papa M, Yosepovich A, Rechavi G, Rotter V, Oren M, Cancer cells suppress

p53 in adjacent fibroblasts. Oncogene 2009 Feb 12;28(6):933-6. [IF 6.44 #14/132 Oncology

2007].

Gluck I, Simon A.J, Catane R, Pfepfer R, Schachter J, Rechavi G, and Bar J. Malignant

Melanoma patients' germ-line analysis of Thymidine/Guanidine polymorphism in position

309 of the promoter of the Mdm2 gene. Melanoma Res. 2009 August; 19(4): 199-202. [IF 2.077,

15/39 Dermatology, Oncology].

Bar J, Yerushalmi R, Shapira-Frummer R, Kutchuk I, Sulkes A, Gutman H, Catane R, and

Jacob Schachter J. Concurrent Chemobiotherapy with Cisplatin, Dacarbazine, decrescendo

Interleukin-2 and Interferon alpha2b in Patients with Metastatic Melanoma. Oncology

Reports. 2008 Dec;20(6):1533-8. [IF 1.597].

Moskovitz N, Kalinkovich A, Bar J, Lapidot T and Oren M. p53 attenuates cancer cell

migration and invasion through repression of SDF-1/CXCL12 expression in stromal

fibroblasts. Cancer Res. 2006 Nov 15;66(22):10671-6 [IF 7.656, #10/127 Oncology 2006].

Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V and Oren M. Repression of the

MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene.

2006 Jan 19;25(3):359-69 [IF 6.582, #12/127 Oncology 2006].

Bar J, Lukaschuk N, Zalcenstein A, Seger R, Oren M. The PI3K inhibitor LY294002

prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis.

Cell Death and Differentiation. 2005 Jun 3; 12: 1578–87 [IF 7.463, #22/125 Cell Biology 2006].

Bar J, Cohen-Noyman E, Geiger B, Oren M. Attenuation of the p53 response to DNA

damage by high cell density. Oncogene. 2004 Mar 18; 23(12):2128-37 [IF 6.582, #12/127

Oncology 2006].

Lavon I, Pikarsky E, Gutkovich E, Goldberg I, Bar J, Oren M, Ben-Neriah Y. Nuclear

Factor-kappaB Protects the Liver against Genotoxic Stress and Functions Independently of

p53. Cancer Res. 2003 Jan 1; 63(1):25-30 [IF 7.656, #10/127 Oncology 2006].

PhD thesis: Role of p53 in tumor-host interactions. Mentor: Moshe Oren, Weizmann Institute

of Science. Approved Dec 2004.

Book chapters, editorials, reviews, letters:

Onn A, Bar J, Herbst Roy S. Angiogenesis inhibition and lung cancer therapy. Editorial.

Lancet Oncol. 2014 Feb; 15(2): 124 – 125.

Shlomi D, Pekar M, Iluze M, Bar J, Biran H, Navon R, Onn A, Peled N. The Diagnostic

Puzzle of EML4-ALK Rearrangement in Lung Cancer. Review. The Journal of

OncoPathology. 2013 Jul; 1(2): 103-110(8).

8

Bar J, Urban D, Borshtein R, Nechushtan H, Onn A. EGFR mutation in lung cancer: tumor

heterogeneity and the impact of chemotherapy. Editorial. Chin Clin Onc. 2012 Dec 11. DOI:

10.3978.

Bar J, Shiran I, Urban D, Agbarya A, Onn A. Anti-angiogenic treatments in advanced

NSCLC: back to the drawing board. Editorial. J Thorac Dis. 2012 Oct 18. DOI: 10.3978.

Bar J, Goss G. Tumor vasculature as a therapeutic target in Non-small Cell Lung Cancer.

Journal of thoracic oncology. Review. March 2012; 7(3): 609–620. [IF 4.040, #50/185

Oncology,

#7/46 Respiratory System].

Bar J, Herbst R and Onn A. Overcoming resistance to EGFR TKIs in lung cancer. Review.

Clinical Lung Cancer. On line Dec 2011 [IF 2.393].

Bar J, Wheatley Price P. Advances in liposomal formulations for targeting lung cancer

(2011). In: Ed. Souto EB. Lipid Nanocarriers in Cancer Diagnosis and Therapy. Special

handbook edition. Shrewsbury, UK: iSmithers Rapra Publishing. pp. 257-278.

Livneh J, Waddington K and Bar J. Addressing Safety Issues of Health Care Personnel,

Family Members, and the Environment. Letter. Journal of Clinical Oncology. 2010 February

16; published online [IF 17.157].

Bar J, Moskovits N and Oren M. Involvement of stromal p53 in tumor-stroma interactions.

Review. Seminars in Cell and Developmental Biology. 2010 February; 21(1):47-54 [IF 4.528].

Bar J, Onn A and Herbst RS. Molecular Events Surrounding the Angiogenic Switch of Lung

Cancer. In: Eds. Pass H. Carbone DP, Johnson DH, Minna JD, Scagliotti GV and Turrisi AT

III. Principles and Practice of Lung Cancer, the official reference text of the IASLC:, 4th Ed.,

Lippincott, Philadelphia, PA. 2010.

Bar J, Herbst RS, and Onn A. Targeted drug delivery strategies to treat lung metastasis.

Review. Expert Opinion on Drug Delivery. 2009 October; 6(10):1003-1016 [IF 3.345, 2009].

Bar J, Herbst RS, and Onn A. Multi-Targeted Therapeutics in Lung Cancer: New Clinical

Data. Review. Clinical Lung Cancer. 2008 May 15;9(sup3):S92-S99.

Bar J and Onn A. Combined anti-proliferative /anti-angiogenic strategies for cancer. Review.

Expert Opinion on Pharmacotherapy. 2008 Apr;9(5):701-15. [IF 2.077, 123/216 Pharmacology

& Pharmacy 2008].

Frommer-Shapira R, Bar J, Kuchuk, I, Catane, R and Schachter, J. Chemobiotherapy in

metastatic melanoma patients: the Sheba experience. Melanoma Research.

2007 Feb; 17(1): A27-A28.

Bar J, Ehrenfeld M, Rozenman J, Perelman M, Sidi Y, Gur H. Pulmonary-renal syndrome in

systemic sclerosis. Review. Semin Arthritis Rheum. 2001 Jun;30(6):403-10.

International conferences presentations:

Poster: A. Ben Nun, N. Golan, E. Ofek, D. Urban, I. Kamer, D. Simansky, A. Onn, A.

Ackerstein, S.P. Raskin, T. Shulimzon, N. Zeitlin, I. Redinsky, S. Halperin, M. Jurkowicz and

J. Bar. Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer

(NSCLC) – initial report of a phase I study, MK3475-223. Poster presentation at ESMO

annual meeting 2018.

Poster: J. Bar, K. Shulman, T. Kuznetsov, G. Markel, S. Daher, R. Berger, T. Golan, D.

Urban, T. Sela, E. Shacham Shmueli, R. Klempfner, A. Talianski, A. Onn, E. Dudnik

9

Evaluation of a possible link between immunotherapy (IO) and acute vascular events. Poster

presentation at ESMO annual meeting 2018.

Poster discussion: B C Cho R Perets J Bar M-J Ahn D-W Kim K Yoh A Nagrial D R

Spigel D H Lee M Gutierrez D Kotasek S Siddiqi A Chain B D Butts Y Zhang X Li J

Cyrus A Tse R A Altura D Rasco. Phase I study of the CTLA-4 inhibitor MK-1308 in

combination with pembrolizumab in patients with advanced solid tumors. Annals of

Oncology, 29(suppl 8)1 October 2018, mdy279.402,

https://doi.org/10.1093/annonc/mdy279.402

Poster: Gottfried M, Maimon N, Mishaeli M, Dudnik J, Wollner M, Bar J, Onn A, Frenkel

O, Keren SR. Correlation between erlotinib-induced rash and efficacy in first-line therapy of

patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth

factor receptor (EGFR)-mutation: A prospective multi-center, open-label, single-arm, phase II

study. 150P April 2018. Journal of Thoracic Oncology 13(4):S90-S91

DOI10.1016/S1556-0864(18)30424-6

Oral Presentation: Dudnik E, Peled N, Wollner M, Onn A, Agbareya, A Nechushtan H,

Kuznetsov T, Roisman L, Belilovski Rozenblum A., Geva S, Zer A, Bar J. BRAF Mutant

NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-

BRAF Therapy. MA 02.06, Journal of Thoracic Oncology. November 2017, 12, (11), Sup. 2,

S1804–S1805. DOI: https://doi.org/10.1016/j.jtho.2017.09.455

Oral presentation: Bar J. Tissue taking and testing, NSCLC, The impact of multi-disciplinary

team. 8th Regional Oncology Forum, October 2017, Warsaw, Poland. Invited speaker.

Oral presentation: Bar J. Immunotherapy for lung cancer – elusive targets. Abstract

discussion. ESMO annual meeting. Madrid, Spain, September 2017. Invited Speaker.

Oral presentation: Bar J. Immunotherapy in locally advanced and metastasized NSCLC: 2nd

line, 1st line, liftoff!. European Respiratory Society International Congress. Milano, Italy,

September 2017. Invited Speaker.

Poster: Kamer I, Bar J, Bab-Dinitz L, Zadok O, Daniel-Meshulam I, Onn A.

Immunotherapies evaluation in an Ex-vivo culture model of NSCLC. Poster presentation.

Yokohama, Japan, November 2017, World Conference on Lung Cancer.

Oral presentation: Dudnik E, Peled N, Wollner M, Onn A, Agbareya A, Nehushtan H,

Kuznetsov T, Roisman CL, Zer A, Bar J. On behalf of the Israel Lung Cancer Group. BRAF

mutant NSCLC: correlation with PD-L1 expression, TMB, MSI and response to ICPi and

anti-BRAF therapy. Yokohama, Japan, November 2017, World Conference on Lung Cancer.

Abstract: WINTHER- a Study of Cancer Therapy Based on Tumor and Normal-Matched

Biopsies e the Sheba Medical Center Lung Cancer Experience. T. Sella, A. Ackerstein, S.

Halperin, G. Hout-Siloni, S. Lieberman, I. Barshack, H. Nechushatan, R. Berger,J. Bar, A.

Onn. Yokohama, Japan, November 2017, World Conference on Lung Cancer. Journal of

Thoracic Oncology 12(11), sup 2, S2283. DOI: https://doi.org/10.1016/j.jtho.2017.09.1655

Poster: Modeling immunotherapy in ex vivo organ culture of non-small cell lung cancer

(NSCLC). Bar J, Daniel-Meshulam I, Onn A, Ben-Nun A, Simansky D, Zeitlin N, Golan N,

Rokah M, Ben-Avi R, Kamer I. Abstract 4910. AACR annual meeting, New Orleans, LA,

April 2016.

Abstract: A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-

small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI)

resistance. Bar J, Botser D, Navon R, Peled N, Biran H, Nili Gal-Yam E, Ben-Arieh S,

Raskin S, Onn A; J Clin Oncol 33, 2015 (suppl; abstr e19031).

10

Abstract: Prognostic impact of first treatment choice in EGFR mutant non-small cell lung

cancer (mNSCLC) patients (pts) per mutation type; retrospective analysis. Bar J, Gottfried

M, Dudnik J, Flex D, Keren-Rosenberg SP, Agbarya A, Onn A, Moskovitz MT, Maimon N,

Lazarev I, Peled N, Popovits-Hadari N, Biran H, Urban D, Herscovici L, Wollner M. J Clin

Oncol 33, 2015 (suppl; abstr e19120).

Poster: New ARCHITECT plasma pro-gastrin-releasing peptide assay and lung cancer:

Implications for diagnosis, follow-up, and prognosis. Nisman B, Nechushtan H, Biran H,

Peled N, Gantz-Sorotsky H, Doviner V, Perelman M, Bar J, Uziely B, Peretz-Yablonski T; J

Clin Oncol 33, 2015 (suppl; abstr 7570).

Poster: miR profiling identifies CDK6 down-regulation as a potential mechanism of acquired

cisplatin resistance in non-small cell lung carcinoma. Bar J, Gorn-Hondermann I, Moretto P,

Niknejad N, Stewart DJ, Goss GD, Dimitroulakos J. Poster 154P ESMO 2014 Congress, 26-

30 September, Madrid, Spain.

Poster: Stromal FoxM1 and p53 in lung cancer as mediators of tumor progression, metastatic

spread and chemo-resistance. Kamer I, Daniel I, Perry G, Onn A, Bar J. Abstract 1153. AACR annual meeting, San Diego, CA, April 2014.

Poster: Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald)

serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial. Bar

J, Ding K, Zhao H, Laurie SA, Shepherd F, Addison C, Goss GD, Dimitroulakos J, Bradbury

PA. Abstract 8048. ASCO annual meeting, Chicago, IL, June 2013.

Poster: Activating transcription factor 3 (ATF3) down-regulation correlates with platinum

resistance in non-small cell lung cancer (NSCLC). Bar J, Gorn-Hondermann I, Stephanie R,

Moretto P, Shiran I, Jessel S, Perelman M, Heller E, Kamer I, Daniel-Meshulam I, Goss GD,

Dimitroulakos J. Abstract 895. AACR annual meeting, Washington DC, May 2013.

Abstract: Correlation of lactate dehydrogenase (LDH) isoenzyme profile with outcome in

advanced colorectal cancer (CRC) patients (pts) treated with chemotherapy and bevacizumab

(BEV) or cediranib (CED). Bar J, Spencer S, Morgan S, Pike L, Cunningham D, Robertson

J, Jürgensmeier JM, Goss GD. Abstract e13541. ASCO annual meeting, Chicago, IL, June

2012.

Poster: The efficacy of pemetrexed-based treatment for advanced non-small cell lung cancer

(NSCLC), as correlated with the pathologic features of tumors. Shiran I, Borshteen R, Urban

D, Onn A, Biran H, Bar J. 3rd European Lung Cancer Conference (ELCC), 18-21 April

2012, Geneva, Switzerland.

Poster: Interdisciplinary Thoracic Pathology Meetings: Addressing Competency-Based

Education. Gomes M, Souza C, Bar J, Sekhon H. Pulmonary Pathology Society Biennial

Meeting, New York, NY, USA, August 2011.

Oral presentation: Chemoradiotherapy for recurrent NSCLC; retrospective database analysis

of two large cancer centers. Ng D, Moretto P, Goss GD, Nicholas G, Laurie S, Sun A, Leighl

N, MacRae R, Bar J. Abstract 824, 14th World Conference on Lung Cancer, Amsterdam,

The Netherlands, July 2011.

Abstract: Activating transcription factor 3 (ATF3) as a potential biomarker of platinum

sensitivity in non-small cell lung cancer (NSCLC). Bar J, Gorn-hundermann I, Reid S,

O’Brien A, Niknejad N, Goss GD, Dimitroulakos J. ASCO annual meeting, Chicago, IL, June

2011.

Poster: microRNA (miR) analysis as a tool for discovering platinum resistance mechanisms

11

in non-small cell lung cancer (NSCLC). Bar J, Perez-Iratxeta C, Gorn-hundermann I, Reid S,

Goss G, Dimitroulakos J. Abstract #4949, 102th annual AACR meeting, Orlando Fl, April

2011

Poster: microRNA (miR) profiling of lung cancer cells reveals Cyclin Dependant Kinase 6

(CDK6) as a regulator of platinum sensitivity. Bar J, Perez-Iratxeta C, Gorn-hundermann I,

Reid S, Goss GD, Dimitroulakos J. 11th Annual Targeted Therapies of Lung Cancer meeting,

Santa Monica, CA, February 2011.

Poster: Interdisciplinary Thoracic Pathology Meetings: Addressing Competency-Based

Education. Gomes M, Souza C, Bar J, Sekhon H. Pulmonary Pathology Society 2011

biennial meeting, MSKCC, NYC, August 2011.

Poster: Interdisciplinary Site-Specific Didactic Meetings: Addressing Competency-Based

Education and Program-Based Clinical Services. Gomes M, Souza C, Bar J, Sekhon H. The

International Conference on Residency Education. Quebec city, Canada, September 2011.

Poster: Activating transcription factor 3 (ATF3) as a potential biomarker of platinum

sensitivity in non-small cell lung cancer (NSCLC). Bar J, Gorn-hundermann I, Reid S,

O’Brien A, Goss GD, Dimitroulakos J. 11th Annual Canadian Oncology Winter Conference,

February 2011.

Poster: Metastasis suppressing/promoting microRNA expression in primary and metastatic

colorectal cancers. Vickers M, Asmis T, Jonker D, Maroun J, Yarom N, Bar J, Gorn-

Hundermann I, Daneshmand M, Dimitroulakos J. ESMO, Milano Italy, Sept 2010.

Abstract: Optimization of microRNA extraction from formalin fixed paraffin embedded

colorectal and lung cancer tissues, and validation of a microRNA internal control. Bar J,

Gorn-Hundermann I, Vickers M, Dimitroulakos J. ESMO, Milan Italy, Oct 2010.

Poster: Cancer cells suppress p53 in adjacent fibroblasts. Bar J., Feniger-Barish R.,

Moskovits N, Lukashchuk N, Goldfinger N, Rotter V, Goss G, Oren M. 13th World

Conference on Lung Cancer. July 2009, San Francisco, California, USA. Abstract 6752.

Poster: Cancer Cells Inhibit the Activation of p53 by DNA Damage in Neighboring Stromal

Cells. Bar J, Feniger-Barish R, Lukaschuk N, Shaham H, Moskovitz N, Oren M. The 4th

International Conference On “Tumor Microenvironment: Progression, Therapy and

Prevention”, Florence, Italy, 2007.

Poster: Cancer Cells Inhibit the Activation of p53 by DNA Damage in Neighboring Stromal

Cells. Bar J, Lukaschuk N, Shaham H, Moskovitz N, Oren M. Cancer, Proteases, and the

Tumor Microenvironment, an AACR special conference, Florida, USA, 2005.

Poster: Attenuation of the p53 response to DNA damage by high cell density. Bar J, Wilder

S, Cohen-Noyman E, Oren M. 11th international p53 workshop, Barcelona, Spain, 2002.

Awards and competitive grants:

2018 Best abstract ISCORT award

2018 Investigator-Initiated clinical study approval by AstraZeneca Inc.

2018 MOH research grant

2017 List of 'best doctors of Israel' Forbes magazine (based on peer review).

2015 Investigator-Initiated clinical study approval by Merck Inc.

2014 Sheba Medical Center research grant.

12

2012 Sheba Medical Center research grant.

2012 Israeli Science Ministry “Nofar” fund.

2011 Israel Cancer Association research grant.

2011 Israel Science Foundation personal research grant.

2011 Amgen Canada Fellows ASCO CME program.

2011 Canadian Oncology Winter Conference award.

2010 Ottawa Regional Cancer Foundation research grant.

2010 Canadian Oncology Winter Conference award.

2009 Canadian Oncology Winter Conference award.

2008 Dr. Kline/Ms. Merkis Award, American Physicians Fellowship.

2007 Israel Cancer Association grant (joint grant with Dr. Pfepfer, Sheba MC).

2007 Van Bates grant from the Tel Aviv University Cancer Biology Research Center

(joint grant with Dr Tsarfati, TAU).

2006 Young Investigator prize, ISCORT 2006.

2005 Bloch foundation research award.

2005 Young Investigator prize, ISCORT 2005.

2004 Research Grant from TEVA pharmaceuticals.

1998-99 Research grant from the Israel Cancer Association.

1998-99

1993 B. Med Sc. Magna Cum Laude